President Trump tonight on the verge of signing an executive order that would change the future of cannabis in the United States. Four sources tell NBC News the EO would fasttrack the rescheduling of marijuana, moving it into a category with lower risk drugs. >> A lot of people want to see it, the reclassification, because it leads to tremendous amounts of research that can't be done unless you reclassify.Since 1970, the drug has been listed as a schedule one substance in the same category as heroin and LSD ...

Market Trends - The cannabis craze is partly driven by seniors who started using cannabis over 15 years ago [1] - Analysis indicates that over 50% of current senior cannabis users began using it more than 15 years ago [1]

Market Trend & Regulatory Landscape - Cannabis stocks are soaring on reports of potential marijuana reclassification by the president [1] - The president is considering reclassifying marijuana from Schedule I (on par with heroin) to Schedule III (similar to Tylenol with codeine) [2] - An executive order advising the DOJ and DEA to move forward with reclassification could be issued as soon as Monday [2] - The DOJ and DEA will publish a final rule, followed by a 30-day waiting period for challenges, after the executive order [4] - Opposition exists, as evidenced by the recent hemp ban in the government spending bill, which could lead to litigation and further delays [4] - Reclassification is not legalization, but a partial victory that opens the door to medical research [5][6] Industry Insights & Company Strategy - Tilray's CEO is optimistic about change by the end of the year, despite past false starts [3] - The industry hopes for broader federal legalization to open up recreational use products [8] - Amplifying medical use is a key avenue, with potential support from figures like Secretary RFK Jr [7][8] - Reclassification has major implications for health regulators, retailers, investors, and banks [5]

Policy Change - US administration is expected to reclassify marijuana as a less dangerous drug [1] - This could be one of the biggest shifts in US policy toward cannabis in decades [1] Market Reaction - Shares of pot stocks surged premarket [1]

Industry Focus - The cannabis industry is a key area of interest, given Anutin Charnvirakul's background as a cannabis champion [1] Leadership & Politics - Anutin Charnvirakul's ability to lead Thailand out of crisis is questioned [1] - The stability of Anutin Charnvirakul's coalition is uncertain [1]

Law Enforcement - A man was arrested in County Wexford after €1.6 million of cannabis was seized [1]

Market Trend - Nicotine pouches have paved the way for THC-infused pouches to become the next big trend in cannabis [1] Company Insight - Cannadips cofounder Case Mandel believes in the potential of THC-infused pouches [1]

Industry Focus - Pharmaceutical cannabis is considered the biggest future for cannabis industry [1] - Ajna BioSciences, founded by Joel Stanley, has a botanical drug in the FDA pipeline [1] Company Information - Joel Stanley (with his brother Jared) is the founder of Ajna BioSciences [1] - Charlotte's Web provided the photo [1]